Medicare Enrolled
Dr. Myassar Zarif, MD
Neurology · Islip, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Zarif from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zarif?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zarif
Dr. Myassar Zarif is a neurology specialist in Islip, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Zarif performed 24,522 Medicare services across 1,556 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zarif received a total of $520,503 from 64 pharmaceutical and/or device companies across 1164 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zarif is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in NY
$520,503 industry payments
Medicare Practice Summary
Medicare Utilization ↗24,522
Medicare services
Top 3% in NY for neurology
1,556
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,226 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, natalizumab, 1 mg | 18,040 | $19 | $30 |
| Ocrelizumab infusion (Ocrevus) for MS | 3,607 | $46 | $70 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
675 | $106 | $372 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
459 | $19 | $134 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
369 | $4 | $32 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
292 | $57 | $384 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
244 | $84 | $371 |
| New patient office visit, complex (60-74 min) | 172 | $191 | $821 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
86 | $1 | $21 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
79 | $14 | $131 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
60 | $145 | $494 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
57 | $8 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
54 | $12 | $133 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
54 | $1 | $10 |
| Lumbar puncture for diagnostic test A procedure to remove cerebrospinal fluid from the lower back for diagnostic testing. |
42 | $126 | $1,691 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
38 | $29 | $179 |
| Optic nerve imaging (OCT scan) Imaging of the optic nerve. |
37 | $34 | $272 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 36 | $0 | $0 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
29 | $36 | $335 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
29 | $147 | $1,125 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
24 | $144 | $889 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
14 | $31 | $360 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
13 | $110 | $469 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
12 | $82 | $494 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
18.2% high complexity
76.2% medium
5.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$520,503
Total received (2018-2024)
Avg $74,358/year across 7 years
Top 2% in NY for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
64
Companies
1,164
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$507,699 (97.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,193 (1.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,610 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$19,742
2023
$51,599
2022
$101,860
2021
$46,078
2020
$69,036
2019
$138,842
2018
$93,345
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$18,842
Biogen, Inc.
$263
Novartis Pharmaceuticals Corporation
$188
Mallinckrodt Hospital Products Inc.
$182
Alexion Pharmaceuticals, Inc.
$122
EMD Serono, Inc.
$120
Celgene Corporation
$24
Top 3 companies account for 97.7% of 2024 payments
All-time payments by company (2018-2024) ›
Biogen, Inc.
$173,291
Horizon Therapeutics plc
$83,663
GENZYME CORPORATION
$51,979
Teva Pharmaceuticals USA, Inc.
$47,882
Alexion Pharmaceuticals, Inc.
$32,682
Genentech USA, Inc.
$29,034
EMD Serono, Inc.
$28,117
Novartis Pharmaceuticals Corporation
$21,017
Amgen Inc.
$19,275
Celgene Corporation
$14,772
E.R. Squibb & Sons, L.L.C.
$11,303
Acorda Therapeutics, Inc
$3,150
Mallinckrodt Hospital Products Inc.
$613
Mallinckrodt LLC
$287
Greenwich Biosciences, Inc.
$257
Lundbeck LLC
$214
Neurelis, Inc.
$207
PFIZER INC.
$163
Medtronic, Inc.
$156
Allergan, Inc.
$153
Adamas Pharmaceuticals, Inc.
$138
ARGENX US, INC.
$136
Boston Scientific Corporation
$134
AQUESTIVE THERAPEUTICS, INC.
$125
Avanir Pharmaceuticals, Inc.
$119
Eisai Inc.
$109
TG THERAPEUTICS, INC.
$106
Sunovion Pharmaceuticals Inc.
$95
JAZZ PHARMACEUTICALS INC.
$94
AbbVie Inc.
$83
Neurocrine Biosciences, Inc.
$76
HARMONY BIOSCIENCES LLC
$69
ARBOR PHARMACEUTICALS, INC.
$65
ACADIA Pharmaceuticals Inc
$63
Grifols USA, LLC
$59
Collegium Pharmaceutical, Inc.
$58
Avion Pharmaceuticals
$58
Amneal Pharmaceuticals LLC
$54
UCB, Inc.
$54
AstraZeneca Pharmaceuticals LP
$48
ABBVIE INC.
$43
Medtronic USA, Inc.
$42
Alnylam Pharmaceuticals Inc.
$36
SK Life Science, Inc.
$34
Scilex Pharmaceuticals Inc.
$33
W. L. Gore & Associates, Inc.
$31
ASSERTIO THERAPEUTICS, Inc.
$30
Lilly USA, LLC
$30
Supernus Pharmaceuticals, Inc.
$25
Nevro Corp.
$25
LivaNova USA, Inc.
$23
EISAI INC.
$21
IDORSIA PHARMACEUTICALS US INC
$21
ANI Pharmaceuticals, Inc.
$19
Strongbridge US INC.
$18
Promius Pharma LLC
$15
Genentech, Inc.
$15
Impax Laboratories, Inc.
$14
Currax Pharmaceuticals LLC
$13
GE HEALTHCARE
$13
Upsher-Smith Laboratories LLC
$13
Allergan Inc.
$12
Kaleo, Inc.
$12
SANOFI-AVENTIS U.S. LLC
$7
Top 3 companies account for 59.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ACTIVA · ADUHELM · AIMOVIG · AJOVY · AMPYRA · ANDEXXA · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aduhelm · Aimovig · BOTOX · BOTOX THERAPEUTIC · BRILINTA · BRIUMVI · Briviact · CARDIOFORM Septal Occluder · COMIRNATY · CONTRAVE · COPAXONE · Cambia · Dhivy · EMGALITY · EVUSHELD · Epidiolex · Evzio · GILENYA · GOCOVRI · Gamunex-C · Horizant · INBRIJA · INGREZZA · KESIMPTA · KEVEYIS · LEMTRADA · LYRICA · MAVENCLAD · MAYZENT · MS DISEASE STATE · Mavenclad · NO PRODUCT DISCUSSED · NORTHERA · NUEDEXTA · NUPLAZID · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONFI · ONPATTRO · Ocrevus · Omnia · Ongentys · Ozanimod · PANZYGA · PERCEPT PC BRAINSENSE · PLEGRIDY · PURIFIED CORTROPHIN GEL · QELBREE · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUVIVIQ · RESTORE · REYVOW · RYTARY · Rebif · SOLIRIS · SUNOSI · SYMPAZAN · SYNCHROMEDII · Soliris · TECFIDERA · TROKENDI XR · TYSABRI · Tysabri · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VNS Therapy · VUMERITY · VYEPTI · VYVGART · WATCHMAN FLX · Wakix · XTAMPZA · XTAMPZAER · XYREM · XYWAV · Xtampza ER · ZEPOSIA · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH · Zembrace
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for neurology in NY.
Geographic Context
Neurologists within 10 mi
186
Per 100K population
12.2
County median income
$128,329
Nearest hospital
NS/LIJ HS SOUTHSIDE HOSPITAL
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Zarif is a mixed practice specialist, with above-average Medicare volume (top 3% in NY), with speaking/promotional industry engagement in the top 2% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Zarif experienced with injection, natalizumab, 1 mg?
Based on Medicare claims data, Dr. Zarif performed 18,040 injection, natalizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zarif receive payments from pharmaceutical companies?
Yes. Dr. Zarif received a total of $520,503 from 64 companies across 1,164 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zarif's costs compare to other neurologists in Islip?
Dr. Zarif's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zarif) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Islip
Browse neurologists in Islip ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in NY
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in NY
Which NY neurologists receive the most from drug and device companies.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
By company
Horizon Therapeutics plc Payments to Doctors
See all physicians who received payments from Horizon Therapeutics plc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology